Simvastatin Articles
US seniors' Rx cost rises "are double inflation"
15 June 2001
Stock Commentary - Tokyo
14 June 2001
Tokyo stock comment
12 June 2001
Nu-lotan driving sales at Banyu
8 June 2001
Merck & Co sales leap 28%; EPS up 13%
23 April 2001
Pravastatin action on CRP a class effect?
17 April 2001
Tokyo pharma stock market - week to March 26, 2001
27 March 2001
Stroke prevention emerges from heart disease
10 January 2001
Merck & Co reiterates independence at pipeline presentation
14 December 2000
Antithrombotic delay mars upbeat AstraZeneca R&D meeting
13 December 2000
Compare US Rx drug prices, consumers told
27 September 2000
Stock Commentary Tokyo
17 August 2000
Merck & Co posts strong sales growth
25 July 2000
Merck's Zocor lowers CRP
29 June 2000
Japan Lipitor launch: a threat for statins
19 June 2000
Stock Commentary Tokyo
18 May 2000
W-L sets price for Lipitor in Japan
3 May 2000
Japan majors' price cuts will average 6%
13 March 2000
Stock Commentary Tokyo
9 March 2000
Swedish pharma sales rose 11.2% in 1999
6 March 2000
Japan's Banyu upgraded by analysts
2 March 2000
Stock Commentary Tokyo
3 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Merck's Zocor "reduces heart disease risk by 42%"
16 December 1999
Stock Commentary Tokyo
16 December 1999
Banyu results strong despite Lipovas decline
24 November 1999
Stock Commentary Tokyo
21 October 1999
Banyu forecasts strong profits for 2004
11 October 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Merck granted expanded Zocor labeling
11 August 1999
US DTC Rx ad spend hit $1.3 billion in 1998
25 May 1999
Mevacor approved for primary prevention
18 March 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
Swedish pharma market sees 16.2% growth for 1998, says LIF
12 February 1999
New drugs boost Sanofi's 1998 sales
27 January 1999
New drugs boost Sanofi's 1998 sales
25 January 1999
Cholestagel filing planned for mid-year
12 January 1999
Merck "Get To Goal" Guarantee for Zocor
6 November 1998
Novartis FAME Study For Primary Prevention In Elderly
4 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Merck's Zocor Licensed in UK
3 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
W-L's Lipitor "Will Be World Top-Seller In 2005"
3 August 1998
Sanofi Produces Strong First-Half Sales Growth
24 July 1998
US Drug Stocks Plummet After Merck Disappoints
23 July 1998
New Doses For Merck's Zocor
22 July 1998
Strong 1st Qtr Growth In Swedish Pharma Market
15 May 1998
US Quarterly Financial Results Round-Up
23 April 1998
Analysts Forecast Bright Outlook For US Majors
8 April 1998
Rx Drug Sales In USA Grew 12.6% Last Year
6 April 1998
FDA OKs Two Statins For Stroke Prevention
2 April 1998
Canada's Generics Firms Outraged At Patent Moves
17 March 1998
Zocor Cuts Stroke, Says AJC Study
25 February 1998
Sanofi Pharma Sales Held Back In West Europe, But Up 10%
4 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
FDA Issues Talk Paper On Posicor Interactions
2 January 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
News In Brief
11 December 1997
...Merck Confident It Can Hold Growth Rates
9 December 1997
3rd-Qtr Rx Drug Prices Up 2.9%, Generics Fall 6.4%
25 November 1997
News In Brief
7 November 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
US DTC Advertising Is Fastest Growing Promotional Segment
21 October 1997
Merck's Sales Up 19% Amid Fears For The Future
17 October 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
New Studies At European Cardiology Meeting
15 September 1997
GW's Zantac Knocked Off Top US Rx Drug Spot
4 September 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
India's Kopran Plans Product Launches
17 July 1997
Stock Comment New York
17 July 1997
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
